Chronic kidney disease (CKD) and type 2 diabetes (T2D) together present a major health, social, and economic burden in the 21st century. Individuals with CKD and/or T2D are at high risk for accelerated vascular aging, which significantly increases their likelihood of developing cardiovascular disease (CVD). Despite current treatment options, the complexity of these conditions makes personalized care difficult to achieve. Recent research suggests that calprotectin, an inflammatory protein linked to cellular damage, may function both as a biomarker and as a therapeutic target in vascular aging associated with CKD and T2D. The EU-Calprotect project is designed to advance the use of calprotectin in clinical settings, positioning it as a biomarker that could be paired with targeted therapies to slow down premature vascular aging. The potential impact of the EU-Calprotect project is substantial, as it may pave the way for a more tailored approach to managing cardiovascular risk in patients with CKD and T2D. By focusing on individualized care, this project aims not only to improve patients’ quality of life but also to reduce the long-term economic burden associated with these chronic conditions.